Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yifei Sanjie Wan (0461db)
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Administration
- Oral
01
Overview
Yifei Sanjie Wan is a Traditional Chinese Medicine (TCM) formula developed by The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine for the treatment of mid-to-late stage non-small cell lung cancer (NSCLC). The formula is based on the 'Yiqi Chutan' therapeutic principle, which aims to replenish vital energy (Qi) and eliminate phlegm and nodules. In clinical practice, it is often evaluated as an adjuvant therapy in combination with platinum-based chemotherapy doublets, particularly for patients who are negative for common driver mutations (e.g., EGFR, ALK). The treatment is intended to enhance the efficacy of chemotherapy, reduce adverse effects, and improve the overall quality of life for lung cancer patients.
- Other names
- Yiqi Chutan Fa
02
Targets
STAT3 (Signal Transducer and Activator of Transcription 3)FXR (Farnesoid x-activated receptor)BNIP3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3)PIK3CA (Phosphoinositide 3-kinase alpha)HIF1A (Hypoxia-inducible factor 1-alpha)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)EGFR T790M (Epidermal growth factor receptor T790M mutant)USP7
Beyond the preview
Go deeper on Yifei Sanjie Wan (0461db).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yifei Sanjie Wan (0461db).